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Abstract
Background: Reports on the association between hypertension and insulin resistance have been inconsistent even though
most studies show a definite association. It is also not certain if the association between insulin resistance and hypertension
applies to all populations.
Objective: To determine the prevalence of  insulin resistance in hypertensive Nigerians and to examine the association of
insulin resistance with hypertension and some anthropometric indices.
Methods: Thirty five adults with essential hypertension and thirty five normotensives were studied. Anthropometric
parameters, blood pressure, fasting glucose and insulin were measured. Homeostasis model assessment (HOMA) was
used to determine insulin resistance (IR).
Results: The hypertensive subjects had significantly higher fasting insulin and HOMA-IR compared with normotensives
(p =0.02 and 0.04) respectively. There were significant correlations between HOMA-IR, BMI, waist and hip circumference in
subjects with hypertension. At multiple linear regression, hypertension and body mass index were found to be the only
significant predictors of insulin resistance.
Conclusion: The hypertensives we studied had a higher occurrence of insulin resistance compared to the normotensives.
This makes it necessary for persons with hypertensive to have regular screening for diabetes and other categories of glucose
intolerance as the increased insulin increases their risk of developing type 2 diabetes mellitus.
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Introduction
Hypertension is an important medical and public
health problem in both developed and developing
countries. It affects 25% of  the adult population
worldwide and its prevalence is predicted to increase
by 60% by 2025, when a total of 1.56 billion people
may be affected1. Essential hypertension accounts
for as many as 95% of cases of hypertension2.
Hypertension and type 2 diabetes mellitus (DM) are
interrelated metabolic disorders that strongly
predispose an individual to macrovascular and
microvascular complications. In recent years insulin
resistance has been shown to play a central role in
the development of hypertension, diabetes, obesity
and dyslipidaemia.
Insulin resistance, a pathological situation
characterised by reduced tissue sensitivity to insulin
and marked compensatory hyperinsulinemia has
continued to generate interest. It has been implicated
in the pathogenesis of type 2 diabetes mellitus and
essential hypertension and is closely associated with
dyslipidaemia, coronary artery disease, obesity and a
cluster of metabolic and cardiovascular
abnormalities that define the metabolic syndrome 3,
4.
The progression from normal glucose
tolerance to type 2 diabetes mellitus is characterised
by dual defects that include insulin resistance and an
insulin secretory defect caused by beta cell
dysfunction5. Insulin resistance is said to precede the
development of impaired glucose tolerance (IGT)
and type 2 DM by decades3. Identifying persons with
insulin resistance who are therefore at risk for
developing type 2 DM would afford an opportunity
for intervention and possible delay or prevention
of  diabetes.
Insulin resistance can be estimated using
several techniques. The euglycaemic hyperinsulinemic
clamp technique is the gold standard method for
evaluation6.  However this method is complex and
expensive. HOMA-IR is a simple and reliable
surrogate measure of insulin resistance7, 8. HOMA
model is derived from a mathematical assessment
of the interaction between beta cell function and
insulin resistance in an idealized model that is then
used to compute steady state insulin and glucose
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concentrations 9, 10. An advantage of the HOMA
method is that only a single venepuncture is required
so it is simple and easy to use.
Reports on the association between
hypertension and insulin resistance have been
inconsistent and it is not certain if the association
between insulin resistance and hypertension applies
to all populations. There is also paucity of  data on
insulin resistance among Nigerians with hypertension.
This study aims to determine the prevalence
of insulin resistance in a group of Nigerians with
essential hypertension using the HOMA method and
to examine the relationship between insulin resistance,
hypertension and some anthropometric indices.
Methods
The study population comprised of  70 adults. Thirty
five consecutive persons with essential hypertension
seen at the General Outpatient Clinics of a University
Teaching Hospital formed the study subjects while
35 persons who did not have a history of
hypertension or diabetes and whose measured blood
pressures were normal were recruited as controls.
Controls were recruited consecutively from hospital
staff  and relatives of  our patients.
Hypertension was diagnosed if the systolic blood
pressure was equal to or greater than 140mmHg
and or if the diastolic blood pressure was equal to
or greater than 90mmHg recorded on at least two
occasions or if the person was on antihypertensive
medications. 11 Subjects with secondary hypertension
and persons already diagnosed to have diabetes were
excluded from the study. Other exclusion criteria
included pregnant women and persons with  acute
intercurrent illness or persons receiving medications
known to affect glucose metabolism. Participants
were told to be on their usual diet for the three days
prior to the oral glucose tolerance test. Ethical
clearance was obtained from the local ethics
committee and written informed consent was
obtained from all subjects before participation.
All persons studied had information on age,
gender, tribe and marital status recorded in addition
to weight, height, waist and hip circumference, and
blood pressure. Body mass index (BMI) was
calculated as the weight in kilograms divided by the
height in meters squared. Obesity was defined as a
BMI >30kg/m2 while truncal obesity was defined
as a waist circumference >94cm in males and >80cm
in females. Waist and hip circumference (cm) were
measured with a flexible inelastic tape and the waist
to hip ratio was calculated. Blood pressure was
measured using a sphygnomanometer in the sitting
position after a five minutes rest.
Metabolic studies
Following an overnight fast of  10-12 hours, four
mls of venous blood was drawn from each
participant and divided into equal aliquots for analysis
of the fasting plasma glucose and fasting insulin. The
blood collected for glucose analysis was promptly
centrifuged and analyzed by a glucose oxidase
method with kits from Dialab Diagnostics, Austria
while the blood collected for insulin estimation was
centrifuged and stored at -20oC until analyzed. Serum
insulin levels were determined by Enzyme Linked
Immunosorbent Assay method using instruments
and kits from Diagnostic Automation Incorporated,
Canada. The kit has no cross reactivity with intact
human proinsulins. The intra-assay and inter-assay
coefficients of variation were 6.29 and 7.67
respectively.
Insulin resistance was derived using the homeostasis
model assessment method and was calculated using
the formula: HOMA-IR = Fasting insulin value
(mU/L) X Fasting plasma glucose (mmol/L)/22.59.
Persons with HOMA-IR >3.8 were considered to
have insulin resistance 12.
Data were analyzed with SPSS version 16. Continuous
variables were presented as mean (standard
deviation) and categorical values as no (%).
Comparison between means was done using the t
test for two groups and analysis of variance for more
than two groups. Associations between two
categorical variables were tested using the Chi square
test. Level of significance was p value less than 0.05.
Results
A total of  35 hypertensives and 35 normotensives
were studied. The characteristics of the subjects and
controls are summarised in table 1. The mean age
of the subjects with hypertension was 55.8±10.3
years while the mean age of the controls was 50.5±
9.1 years (p= 0.026). The age range of hypertensives
and controls was 37-80 years and 35 to 75 years
respectively.
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The systolic and diastolic blood pressures in the
hypertensives ranged from 100-182mmHg and 72
to 115mmHg respectively, while in the
normotensives it ranged from 90-132mmHgand  58-
85mmHg respectively. The mean systolic and
diastolic blood pressures in the hypertensive group
was 142.5±16.2 mmHg and 94.5±10.7 mmHg
respectively (p=0.001) while it was 115.8±11.5
mmHg and 76.4±7.3 mmHg in the control group
(p<0.001).
Eleven (31.4%) of the hypertensives and 8(22.9%)
of  the normotensives were obese (p=0.42). Truncal
obesity was present in 71.4% of hypertensive subjects
and 68.6% of the controls though these did not attain
statistical significance. There was no statistically
significant difference in anthropometric indices
between hypertensives and controls even when
analysed according to gender.
Fasting plasma glucose did not differ significantly
between  the 2 groups though fasting insulin
Table 1: Clinical and metabolic characteristics of  hypertensive and control subjects
Parameter Hypertensives Controls P value
(n=35) Mean (SD) (n=35) Mean (SD)
Systolic blood pressure (mmHg) 142.5±16.2 115.8±11.5 0.001*
Diastolic blood pressure (mmHg) 94.5±10.7 76.4±7.3 <0.001*
Weight (kg) 73.6± 14.6 74.3±15.8 0.85
BMI (kg/m2) 27.4±5.8 26.8±5.3 0.69
Waist Circumference (cm) 93.6±13.7 90.0±11.8 0.26
Waist: Hip ratio 0.91±0.1 0.88±0.1 0.17
FPG (mg/dl) 93.1±19.9 89.9±13.3 0.43
FPI (mU/ml) 15.5±5.3 12.9±3.4 0.02*
HOMA-IR 3.6±1.9 2.9±0.9 0.04*
*p<0.05
BMI= body mass index, FPG= fasting plasma glucose, FPI=fasting plasma insulin, HOMA-IR= Homeostasis
model assessment of insulin resistance
concentration and HOMA-IR were significantly
higher in the hypertensive group compared with the
control group (p=0.02 and 0.04 respectively). 31.4%
of  hypertensives and 8.6% of  normotensives had
insulin resistance (p=0.02).
There were significant correlations between HOMA-
IR and BMI (r=0.603, p<0.001), waist circumference
(r=0.477, p<0.004) and hip circumference (r=0.519,
p <0.001) in subjects with hypertension. HOMA-IR
also correlated significantly with waist circumference
(r=0.399, p=0.02) and hip circumference (r=0.383,
p=0.02) in controls.
At multiple linear regression, after adjustment for
age, BMI, waist circumference and blood pressure,
hypertension and BMI were found to be the only
significant predictors of insulin resistance (regression
coefficient 0.736, 95% confidence interval 0.038-
1.434, p=0.04 and regression coefficient 0.115,
confidence interval 0.052-0.177, p=0.001
respectively) (table 2).
Table 2: Linear regression analysis showing factors associated with the presence of  insulin resistance
Regression 95% CI for P value
coefficient (Beta)
(Beta)
Age 0.007 -0.034-0.047 0.74
Hypertension 0.736 0.038-1.434 0.04*
BMI 0.115 0.052-0.177 0.001*
Waist circumference 0.023 -0.015-0.062 0.23
*p<0.05
CI= confidence interval, BMI= body mass index
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A higher percentage of persons using thiazide
diuretics compared with those not using thiazide
diuretics had insulin resistance (p=0.032). For other
antihypertensives (calcium channel blockers,
angiotensin-converting enzyme inhibitors and
centrally acting drugs) being used, there was no
significant difference in insulin resistance between
users and non-users (table 3).
Table 3: Relationship between antihypertensive use and presence of  insulin resistance
Drug type Insulin Not insulin Total Chi2 P value
resistant resistant
n (%) n (%)
Thiazides
No 7 (13.7) 44 (86.3) 51
Yes 7 (36.8) 12 (63.2) 19 4.62 0.032*
Calcium channel blockers
No 8 (16.7) 40 (83.3) 48
Yes 6 (27.3) 16 (72.7) 22 1.06 0.303
ACEIs
No 12(19) 51(81) 63
Yes 2 (25) 6(75) 8 0.159 0.690
Centrally acting drugs
No 12(18.8) 52(81.2) 64
Yes 2 (33.3) 4(66.7) 6 0.729 0.393
*p<0.05
ACEIs - angiotensin-converting enzyme inhibitors
Discussion
In our study fasting insulin concentration and
HOMA-IR were significantly higher in the
hypertensives compared with the normotensives.
Insulin resistance was present in a higher proportion
of hypertensives (31.4% of hypertensives compared
to 8.6% of controls), indicating an increased risk of
subsequent development of type 2 DM in the
hypertensives since insulin resistance is well recognised
as an independent predictive factor for subsequent
development of type 2 DM. Our findings are
consistent with those from other African populations
which have shown that persons with essential
hypertension are more insulin resistant and
hyperinsulinemic compared to normotensive persons
(13-15). Similar findings have also been reported
amongst Iranians with hypertension13.
Studies have shown prevalence of insulin resistance
in hypertensives ranging  between 27-50% 14, 15.
However different methods and different cut offs
were used in assessing insulin resistance in the various
studies. This may make comparisons between studies
difficult.16, 17.
Though our study showed that insulin resistance was
commoner in hypertensives, we also found that 8.6%
of  our normotensives had insulin resistance.  This is
similar to findings by Bonora et al where insulin
resistance was found in 9.6% of the general
population18. Studies have shown that increasing waist
circumference, waist hip ratio and BMI are associated
with increasing insulin resistance, hyperinsulinemia and
glucose intolerance19 . It is noteworthy that the mean
BMI amongst control subjects was in the overweight
range. In addition, the control subjects did not differ
significantly from the hypertensive subjects as regards
the anthropometric indices. Apart from
environmental factors such as overweight and obesity,
researchers have shown that racial and genetic factors
have a role to play in the development of  insulin
resistance. It is probable that some of our controls
may have a  genetic predisposition to insulin resistance
or   had unrecognized or undiagnosed first degree
relative with hypertension or type  2 diabetes making
them to be at an increased risk for insulin resistance
20, 21.
In a study in Ibadan, where this study was done,
prevalence of obesity was found to be 16.7% among
relatively healthy persons22. In our study obesity was
present in 22.9% of the control population. The
higher prevalence we obtained for obesity in our
normotensives may be partly due to the fact that
some of them were first degree relatives of
hypertensives putting them at risk of the metabolic
syndrome of which obesity is a component and may
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also signify a rise in incidence of obesity as is
occurring in some developed nations.
Increased abdominal fat distribution has
been associated with increased incidence of essential
hypertension, type 2 diabetes mellitus and insulin
resistance19. In this study, the greater frequency of
occurrence of insulin resistance along with higher
BMI, waist circumference and waist hip ratios in
hypertensive when compared to controls would
support the concept of the metabolic syndrome in
which there is a clustering of various cardiovascular
risk factors and consequently a higher cardiovascular
risk.
Studies have shown that insulin resistance is
associated with hypertension and a pathogenetic role
in the development of hypertension has been
suggested. There is however still debate regarding
the role and mechanism of insulin resistance in
hypertension. Several mechanisms have been
adduced. One is that insulin resistance contributes to
the development of essential hypertension as it leads
to hyperinsulinemia which can increase arterial
pressure by causing renal sodium retention and
increased sympathetic activity23. Another explanation
is that insulin resistance and the resultant
hyperinsulinemia can lead to renin angiotensin system
activation and intracellular calcium accumulation in
vascular smooth muscle thus leading to elevated
blood pressures24. It is however not certain whether
insulin resistance precedes or is an outcome of
hypertension. This remains to be demonstrated by
more studies aimed at determining the mechanistic
link between insulin resistance and hypertension which
this study did not set out to determine.
Among our study population, insulin
resistance was significantly more in persons using
thiazide diuretics. This has implication on choice of
antihypertensive medications and it would be
desirable to avoid or use thiazides in low doses in
hypertensives that have additional risk factors for
diabetes (obesity, first degree relative with diabetes
or other components of the metabolic syndrome).
Our findings also suggest a need for larger studies
to corroborate our findings and to determine the
mechanistic link between hypertension, insulin
resistance and diabetes in the general population. Even
though the precise mechanisms of insulin resistance
in hypertensives may not be clear, studies have
demonstrated the benefit of  early interventions to
improve insulin sensitivity in these persons25.
Strategies to reduce insulin resistance such as physical
exercise, weight loss and a healthy diet should be
included in the treatment of hypertensive persons in
order to ameliorate insulin resistance and prevent
the development of  type 2 diabetes. A major
limitation of our study was the small sample size
studied which was mainly due to limited funds.
Conclusion
We have shown that insulin resistance occurred more
frequently in the hypertensives compared to the
normotensives studied, and that hypertension and
increased BMI were the only significant predictors
of  insulin resistance. We also showed a positive
correlation between insulin resistance, BMI and waist
circumference. Our findings may also have potential
implications with regards to preventive strategies for
amelioration of insulin resistance and prevention of
type 2 DM amongst persons with systemic
hypertension.
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